In what appears to be a significant reorganization, Gary Reedy, CEO of the American Cancer Society, announced to the staff of the Atlanta-based charity that he will be stepping away from its day-to-day operations.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
